Kymera Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Atlas Venture Fund X, L.P.(6.4%),Atlas Venture Associates X, L.P.(6.4%)等
Kymera Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(10.3%)
Kymera Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Avoro Capital Advisors LLC(9.99%),Behzad Aghazadeh(9.99%)
Kymera Therapeutics | SC 13G:超过5%持股股东披露文件-FMR LLC(7.933%),Abigail P. Johnson(7.933%)
Kymera Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Wellington Management Group LLP(7.17%),Wellington Group Holdings LLP(7.17%)等
Kymera Therapeutics | S-3ASR:“知名成熟发行人”证券注册声明
Kymera Therapeutics | 10-Q:2024财年三季报
Kymera Therapeutics | 8-K:Kymera Therapeutics公布2024年第三季度财务业绩并提供业务最新情况
Kymera Therapeutics | 4:持股变动声明-董事 Esposito Pamela
Kymera Therapeutics | 144:拟议出售证券
Kymera Therapeutics | 4:持股变动声明-董事 Albers Jeffrey W.
Kymera Therapeutics | 144:拟议出售证券
Kymera Therapeutics | 144:拟议出售证券
Kymera Therapeutics | 4:持股变动声明-董事 BVF PARTNERS L P/IL
Kymera Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Baker Bros. Advisors LP(9.3%),Baker Bros. Advisors (GP) LLC(9.3%)等
Kymera Therapeutics | 4:持股变动声明-董事 BAKER BROS. ADVISORS LP
Kymera Therapeutics | 8-K:重大事件
Kymera Therapeutics | 424B5:募资说明书
Kymera Therapeutics | 424B5:募资说明书
Kymera Therapeutics | 10-Q:2024财年二季报
暂无数据
暂无数据